Science of Coagulation

Blood coagulation is an important part of the host defense mechanism required for repair and maintenance of the circulatory system. This complex and multifactorial process has been described to contain two parallel but distinct pathways; hemostasis and thrombosis.

Learn More About Our Science

Why Factor XIa?

Factor XIa is a clinically-validated target for the prevention of thrombosis by selectively inhibiting the activation of the intrinsic (contact) pathway, without impacting normal hemostasis (bleeding) through the extrinsic pathway.

Learn More About Factor XIa

About EP-7041

  • eXIthera’s lead IV candidate EP-7041 is a novel, potent and selective small-molecule Factor XIa inhibitor
  • Completed Phase 1 demonstrating safety, tolerability and ideal clinical PK profile with validated efficacy marker aPTT
  • Established that effective anticoagulation is achievable with a small molecule therapeutic without the danger of increased bleeding risk or the need for a reversal agent
  • Preventing major bleeding events saves lives and will significantly reduce healthcare costs

News

The name of this company, eXIthera, refers to its therapeutic aim, inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants. Its lead drug, an injectable coded EP-7041, has completed a Phase 1 clinical trial in healthy human subjects and moved to a program in cardiac […]
Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor […]